TY  - JOUR
A1  - Shohjahon, Choriyev
A1  - Ozodbek, Eshqobilov
AV  - none
UR  - https://mjstjournal.com/index.php/mjst/article/view/6720
Y1  - 2026/02/02/
KW  - epilepsy; antiseizure medicines (ASMs); new-generation anticonvulsants; brivaracetam; lacosamide; perampanel; cenobamate; monitoring.
ID  - arxiv65490
JF  - Multidisciplinary Journal of Science and Technology
N2  - Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The main goals of treatment are to control seizures, minimize adverse effects, and improve patients' quality of life. In recent years, new-generation antiseizure medicines (ASMs) - brivaracetam, lacosamide, perampanel, cenobamate, cannabidiol, and fenfluramine - have stood out due to diversification of mechanisms and additional clinical options in some pharmacoresistant cases. This article, using an evidence-informed review approach, summarizes indications, efficacy signals, drug-drug interactions, and principles of safety monitoring for these agents. The findings suggest that new-generation ASMs are most often used as add-on therapy; optimal outcomes depend on patient-centered selection tailored to seizure type/syndrome, age and comorbidities, potential drug-drug interactions, and titration rate. In practice, targeted monitoring of treatment retention (persistence), cognitive and psychobehavioral effects, fall risk, and relevant laboratory indicators improves medication safety.
PB  - Center for Tech and Media Research
TI  - NEW-GENERATION ANTICONVULSANTS IN EPILEPSY: PRACTICAL SELECTION AND SAFETY MONITORING
N1  - Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/6720)
ER  -